Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pyrotinib plus nab-paclitaxel in HER2-positive advanced breast cancer
ChiCTR1900023653Phase 2Not yet recruiting
- Sponsor
- Liaoning Province Cancer Hospital
- Start
- Jul 2019
- Modality
- Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Allosteric Modulators → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of pyrotinib and paclitaxel in breast cancer, sponsored by Liaoning Province Cancer Hospital. Primary endpoint: Objective response rate. Planned start Jul 2019; status: not yet recruiting.
02
Drugs
pyrotinibpaclitaxel
03
Conditions
breast cancer
Beyond the preview
Go deeper on ChiCTR1900023653.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR1900023653.